June 4, 2010 (New York, NY) -
Paves the way for a new paradigm in the early diagnosis and management of Alzheimer’s disease – WisTa Laboratories Ltd, a wholly owned subsidiary of
TauRx Pharmaceuticals, announced that they have entered a collaborative R&D agreement with
Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer’s disease (AD) and related disorders are currently being diagnosed and treated.
Through this collaboration, the two companies will develop specific markers that will aid in the diagnostics and management of Tau-protein related AD using brain-imaging technology. The diagnostics they are jointly aiming to develop will have application in disease treatment and potentially disease prevention...
[PDF] TauRx Pharmaceuticals' Press Release -
June 4, 2010 (New York, NY) - Paves the way for a new paradigm in the early diagnosis and management of Alzheimer’s disease – WisTa Laboratories Ltd, a wholly owned subsidiary of TauRx Pharmaceuticals, announced that they have entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany, which could redefine the way Alzheimer’s disease (AD) and related disorders are currently being diagnosed and treated.
Through this collaboration, the two companies will develop specific markers that will aid in the diagnostics and management of Tau-protein related AD using brain-imaging technology. The diagnostics they are jointly aiming to develop will have application in disease treatment and potentially disease prevention... [PDF] TauRx Pharmaceuticals' Press Release -
